 |
Xarelto gets EU CHMP nod
Monday 28 July 2008
Alex Shimmings - Editor
The EU's CHMP has granted a positive opinion to Bayer for its novel oral once-daily anticoagulant Xarelto (rivaroxaban 10mg tablets) for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery, its first indication.
The product, which is being jointly developed with Johnson & Johnson Pharmaceutical Research and Development, is now set to follow Boehringer Ingelheim's oral anticoagulant Pradaxa (dabigatran etexilate) onto the EU market, as the first products in a new wave of oral anticoagulants being developed for a range of acute and chronic uses and which are expected to change clinical practice. Pradaxa was launched in its first market, the UK, in April following EU approval for the same indication (Scrip Online, April 21st, 2008)...
Login to view the full article
- Not a subscriber? Request a FREE trial
- Subscribe to Scrip
- Email to a friend
Comments
No Comments Yet
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Scrip Awards 2008
The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 Scrip Awards.
Read the full story
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
